Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 2, Stephen Salmon a member of the Board of Directors of Biotricity Inc.
(the "Company") and the Company's Compensation Committee, resigned from the
Company's Board of Directors effective May 2, 2022. Mr. Salmon did not advise
the Company of any disagreement with the Company on any matter relating to its
operations, policies or practices.
On May 4, 2022, the Board of Directors of the Company appointed Ronald McClurg
to the Board of Directors to fill the vacancy created by Mr. Salmon's
resignation. There are no arrangements or understandings between Mr. McClurg and
any other persons pursuant to which he was selected as a director, Mr. McClurg
will receive compensation as a non-employee director in accordance with the
company's non-employee director compensation practice. Mr. McClurg has no direct
or indirect material interest in any transaction required to be disclosed
pursuant to Item 404(a) of Regulation S-K. Mr. McClurg has not yet been
appointed to any committees of the board.
Mr. McClurg is a senior financial executive with experience leading the finance,
administrative and IT functions in private and public companies. From 2003 to
2019 , Mr. McClurg was the Vice President, Finance & Administration and Chief
Financial Officer for Incisive Surgical, Inc. Since 2020 Mr. McClurg has been a
consultant.
© Edgar Online, source Glimpses
BIOTRICITY, INC. 
